- Home
- SPHR vs MESO Comparison
SPHR vs MESO Comparison
Compare SPHR & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPHR
- MESO
- Stock Information
- Founded
- SPHR 2020
- MESO 2004
- Country
- SPHR United States
- MESO Australia
- Employees
- SPHR N/A
- MESO N/A
- Industry
- SPHR Services-Misc. Amusement & Recreation
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SPHR Consumer Discretionary
- MESO Health Care
- Exchange
- SPHR Nasdaq
- MESO Nasdaq
- Market Cap
- SPHR 1.4B
- MESO 1.4B
- IPO Year
- SPHR N/A
- MESO N/A
- Fundamental
- Price
- SPHR $37.78
- MESO $10.64
- Analyst Decision
- SPHR Buy
- MESO Buy
- Analyst Count
- SPHR 10
- MESO 4
- Target Price
- SPHR $46.70
- MESO $18.00
- AVG Volume (30 Days)
- SPHR 793.0K
- MESO 226.6K
- Earning Date
- SPHR 05-08-2025
- MESO 02-26-2025
- Dividend Yield
- SPHR N/A
- MESO N/A
- EPS Growth
- SPHR N/A
- MESO N/A
- EPS
- SPHR N/A
- MESO N/A
- Revenue
- SPHR $1,031,650,000.00
- MESO $5,670,000.00
- Revenue This Year
- SPHR $9.75
- MESO $178.09
- Revenue Next Year
- SPHR $2.12
- MESO $305.06
- P/E Ratio
- SPHR N/A
- MESO N/A
- Revenue Growth
- SPHR 16.89
- MESO N/A
- 52 Week Low
- SPHR $23.89
- MESO $5.78
- 52 Week High
- SPHR $50.88
- MESO $22.00
- Technical
- Relative Strength Index (RSI)
- SPHR 62.73
- MESO 40.85
- Support Level
- SPHR $36.91
- MESO $10.60
- Resistance Level
- SPHR $38.25
- MESO $11.26
- Average True Range (ATR)
- SPHR 1.45
- MESO 0.41
- MACD
- SPHR 0.04
- MESO -0.06
- Stochastic Oscillator
- SPHR 62.58
- MESO 12.00
About SPHR Sphere Entertainment Co.
Sphere Entertainment Co is a live entertainment and media company. The firm creates, writes, casts, produces, and tours shows and events. The group has two reportable segments which includeSphere and MSG Networks. Sphere is a next-generation entertainment medium, and MSG Networks operates two regional sports and entertainment networks, as well as a direct-to-consumer (DTC) and authenticated streaming product.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.